波士顿科学Boston Scientific Corporation (BSX) 2007年年度报告「NYSE」.pdf

1、A B e t t e r F u t u r e.LEARN HOW WERE BUILDING IT.2 0 0 7 A N N U A L R E P O R TBoston Scientific CorporationOne Boston Scientific PlaceNatick,MA 01760-Copyright 2008 by Boston Scientific Corporation or its affiliates.All rights reserved.BSCAR2008Profile of a Global Leader One of the worlds larg

2、est medical device companies,with$8.357 billion in sales Sales in more than 100 countries Portfolio of approximately 13,000 products,many with#1 positions A global leader in cardiovascular medicine#1 worldwide in drug-eluting stent market 24 million products shipped More than 13,800 patents issued w

3、orldwide More than$1 billion invested in R&D 37 manufacturing,distribution and technology centers worldwideRevenue in millions|Years06$7,82105$6,28304$5,62403$3,47602$2,91901$2,67300$2,66499$2,84298$2,23497$1,83196$1,55195$1,19194$44993$38092$315$8,35707Note:Information above is accurate as of Decem

4、ber 31,2007.32737CVR.indd 132737CVR.indd 13/14/08 3:38:46 PM3/14/08 3:38:46 PMIn 2007,Boston Scientifi c made signifi cant progress toward restoring sustainable and more profi table growth.This progress included a number of initiatives designed to simplify our business and improve shareholder value.

5、The following are some of our key fi nancial accomplishments for the year:The TAXUS Element stent system is an investigational device.Limited by U.S.Federal law to investigational use.Not for sale in the United States.The TELIGEN ICD is pending approval by the U.S.Food and Drug Administration(FDA)an

6、d is not available for sale in the United States.The cover of our 2007 annual report features computer-aided design drawings of recent Boston Scientifi c technology innovations:our third-generation drug-eluting stent,the TAXUS Element paclitaxel-eluting coronary stent system and our TELIGEN implanta